Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Immuno-oncology firm Elicio launches, raises $30mm in first round

Executive Summary

Elicio Therapeutics announced its launch and $30mm in Series A funding from undisclosed investors. The company is developing cancer vaccines based on MIT's Amphiphile platform, which allows for the targeting and delivery of immunogens to the lymphatic system. Elicio's lead programs are for pancreatic, colorectal, and head and neck cancers, and are slated to enter clinical trials in 2020. The company also has earlier stage projects including vaccines, adjuvants, cell therapy vaccines, and immuno-stimulatory therapies.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register